<博士論文>
アトピー性皮膚炎などの慢性湿疹に対する、芳香族炭化水素受容体(AHR)の内因性リガンドである6-formylindolo3, 2-b-carbazole(FICZ)の治療的効果について

作成者
論文調査委員
本文言語
学位授与年度
学位授与大学
学位
学位種別
出版タイプ
アクセス権
関連DOI
概要 Background: Chronic eczema such as atopic dermatitis imposes significant socio-econo-psychologic burdens on the affected individuals. In addition to conventional topical treatments, phototherapy is re...commended for patients with extensive lesions. Although immunosuppression is believed to explain its primary effectiveness, the underlying mechanisms of phototherapy remain unsolved. Ultraviolet irradiation generates various tryptophan photoproducts including 6-formylindolo[3,2-b]-carbazole (FICZ). FICZ is known to be a potent endogenous agonist for aryl hydrocarbon receptor (AHR); however, the biological role of FICZ in chronic eczema is unknown.
Objective: To investigate the effect of FICZ on chronic eczema such as atopic dermatitis.
Methods: We stimulated HaCaT cells and normal human epidermal keratinocytes (NHEKs) with or without FICZ and then performed quantitative reverse transcriptase polymerase chain reaction, immunofluorescence, and siRNA treatment. We used the atopic dermatitis-like NC/Nga murine model and treated the mice for 2 weeks with either Vaseline1 as a control, FICZ ointment, or betamethasone 17- valerate ointment. The dermatitis score, transepidermal water loss, histology, and expression of skin barrier genes and proteins were evaluated.
Results: FICZ significantly upregulated the gene expression of filaggrin in both HaCaT cells and NHEKs in an AHR-dependent manner, but did not affect the gene expression of other barrier-related proteins. In addition, FICZ improved the atopic dermatitis-like skin inflammation, clinical scores, and transepidermal water loss in NC/Nga mice compared with those of control mice. On histology, FICZ significantly reduced the epidermal and dermal thickness as well as the number of mast cells. Topical FICZ also significantly reduced the gene expression of Il22
Conclusion: These findings highlight the beneficial role of FICZ-AHR and provide a new strategic basis for developing new drugs for chronic eczema.
続きを見る

本文ファイル

pdf med3159 pdf 2.85 MB 663 本文
pdf med3159_abstract pdf 117 KB 246 要旨
pdf med3159_review pdf 165 KB 252 審査結果要旨

詳細

レコードID
査読有無
権利関係
関連PubMed ID
報告番号
学位記番号
授与日(学位/助成/特許)
受理日
部局
登録日 2018.11.05
更新日 2018.11.27